专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008014888A3 IMINO-IMIDAZO-PYRIDINDERIVATE MIT ANTITHROMBOTISCHER AKTIVITÄT 审中-公开
公开(公告)号：WO2008014888A3
公开(公告)日：2008-02-07
申请号：PCT/EP2007/006360
申请日：2007-07-18
申请人： SANOFI-AVENTIS , HEINELT, Uwe , HOFMEISTER, Armin , CZECH, Joerg
发明人： HEINELT, Uwe , HOFMEISTER, Armin , CZECH, Joerg
IPC分类号： C07D471/04 , A61K31/435
摘要： Die Erfindung betrifft Verbindungen der Formel (I) mit antithrombotischer Aktivität, die insbesondere den Protease-aktivierten Rezeptor 1 (PAR1 ) inhibieren, Verfahren zu ihrer Herstellung und Verwendung derselben als Arzneimittel.

2. 发明申请

WO2008155022A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS 审中-公开
标题翻译： PYRROLE DERIVATIVES作为P2Y12 ANTAGONISTS
公开(公告)号：WO2008155022A1
公开(公告)日：2008-12-24
申请号：PCT/EP2008/004459
申请日：2008-06-04
申请人： SANOFI-AVENTIS , KLINGLER, Otmar , CZECH, Joerg , CZECHTIZKY, Werngard , WEISS, Tilo , JUST, Melitta
发明人： KLINGLER, Otmar , CZECH, Joerg , CZECHTIZKY, Werngard , WEISS, Tilo , JUST, Melitta
IPC分类号： C07D401/06 , C07D403/06 , C07D403/14 , C07D405/14
CPC分类号： C07D401/06 , C07D403/06 , C07D403/14 , C07D405/14
摘要： The present invention relates to compounds of the formula (I), in which R1; R2; R3; R4; R5; R6; R7; R8; R9; R10; R11; R12; R13; A; B, D and E have the meanings indicated indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
摘要翻译：本发明涉及式（I）化合物，其中R 1; R2; R3; R4; R5; R6; R7; R8; R9; R10; R11; R12; R13; 一个; B，D和E具有权利要求中所示的含义。式I的化合物是有价值的药理活性化合物。它们对血小板表现出强烈的抗凝集作用，因此表现出抗血栓形成的作用，用于治疗和预防心血管疾病如血栓栓塞性疾病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，并且通常可用于其中存在血小板ADP受体P2Y12的不期望的活化或用于治疗或预防血小板ADP受体P2Y12的抑制的条件。本发明还涉及制备式I化合物的方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。

3. 发明申请

WO2008128647A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS 审中-公开
标题翻译：喹喔啉羧酰胺衍生物作为P2Y12拮抗剂
公开(公告)号：WO2008128647A1
公开(公告)日：2008-10-30
申请号：PCT/EP2008/002790
申请日：2008-04-09
申请人： SANOFI-AVENTIS , NAZARE, Marc , ZECH, Gernot , JUST, Melitta , WEISS, Tilo , HESSLER, Gerhard , CZECH, Joerg
发明人： NAZARE, Marc , ZECH, Gernot , JUST, Melitta , WEISS, Tilo , HESSLER, Gerhard , CZECH, Joerg
IPC分类号： C07D401/12 , C07D401/14 , C07D405/14 , A61K31/4709 , A61P9/10 , A61P7/02
CPC分类号： C07D401/12 , C07D401/14 , C07D405/14
摘要： The present invention relates to compounds of the Formula (I), in which R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
摘要翻译：本发明涉及式（I）的化合物，其中R 1， [R ^{2 ; [R ^{3 ; [R ^{4 ; [R ^{5 ; [R ^{6 ; Z者除外; 一个; B; Ë; X; Q; 焦耳; V; G和M具有权利要求中所示的含义。式（I）的化合物是有价值的药理活性化合物。它们对血小板表现出强烈的抗凝集作用，因此表现出抗血栓形成的作用，用于治疗和预防心血管疾病如血栓栓塞性疾病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，并且通常可用于其中存在血小板ADP受体P2Y12的不期望的活化或用于治疗或预防血小板ADP受体P2Y12的抑制的条件。本发明还涉及式（I）化合物的制备方法，其用途，特别是药物中的活性成分，以及包含它们的药物制剂。}}}}}

4. 发明申请

WO2005011721A2 USE OF A PAK INHIBITOR FOR THE TREATMENT OF A JOINT DISEASE 审中-公开
标题翻译：使用PAK抑制剂治疗联合疾病
公开(公告)号：WO2005011721A2
公开(公告)日：2005-02-10
申请号：PCT/EP2004/007855
申请日：2004-07-15
申请人： AVENTIS PHARMA DEUTSCHLAND GMBH , BARRADEAU, Sebastian , BARTNIK, Eckart , CZECH, Joerg , KLATT, Andreas, R. , LEBERER, Ekkehard , LEEUW, Thomas
发明人： BARRADEAU, Sebastian , BARTNIK, Eckart , CZECH, Joerg , KLATT, Andreas, R. , LEBERER, Ekkehard , LEEUW, Thomas
IPC分类号： A61K38/00
CPC分类号： A61K38/08 , A61K38/45 , C07K16/40 , G01N2333/9121
摘要： The invention refers to the use of a p21 -activated kinase (PAK) inhibitor for the treatment of a joint disease such as osteoarthritis or rheumatoid arthritis or for the treatment of a joint pain and the use of PAK as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.
摘要翻译：本发明涉及使用p21激活的激酶（PAK）抑制剂来治疗关节疾病如骨关节炎或类风湿性关节炎或用于治疗关节疼痛，以及使用PAK作为靶蛋白来发现 PAK抑制剂作为治疗关节疾病的药物。

5. 发明申请

WO2004094470A1 ANALYSE UND VERWENDUNG VON PAR 1 POLYMORPHISMEN ZUR RISIKOABSCHÄTZUNG FÜR KARDIOVASKULÄRE ERKRANKUNGEN 审中-公开
标题翻译：分析与PAR的使用1个心血管疾病风险评估多态性
公开(公告)号：WO2004094470A1
公开(公告)日：2004-11-04
申请号：PCT/EP2004/004035
申请日：2004-04-16
申请人： AVENTIS PHARMA DEUTSCHLAND GMBH , KOZIAN, Detlef , CZECH, Joerg , SIEGLER, Karl-Ernst , DELEUZE, Jean-Francois , RICARD, Sylvain , MACE, Sandrine
发明人： KOZIAN, Detlef , CZECH, Joerg , SIEGLER, Karl-Ernst , DELEUZE, Jean-Francois , RICARD, Sylvain , MACE, Sandrine
IPC分类号： C07K14/72
CPC分类号： C12Q1/6883 , C07K14/723 , C12Q2600/156
摘要： Die Erfindung betrifft Polynukleotidsequenzen umfassend genetische Variationen des PAR 1 Gens an den Positionen 3090 und/oder 3329. Das Auftreten dieser Varianten ist beim Menschen korreliert mit erhöhter Auffälligkeit für bestimmte HerzKreislauferkrankungen. Die Erfindung bezieht sich weiterhin auf Verfahren zum Nachweis dieser genetischen Variationen.
摘要翻译：本发明涉及多核苷酸序列包括在位置3090和/或3329，这些变体在人体中的发生与某些心血管疾病的增加的显眼相关PAR 1基因的遗传变异。本发明还涉及用于检测这些基因变异的方法。

6. 发明公开

EP2148871A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS 审中-公开
标题翻译：喹啉甲酰胺衍生物作为P2Y12拮抗剂
公开(公告)号：EP2148871A1
公开(公告)日：2010-02-03
申请号：EP08735104.5
申请日：2008-04-09
申请人： Sanofi-Aventis
发明人： NAZARE, Marc , ZECH, Gernot , JUST, Melitta , WEISS, Tilo , HESSLER, Gerhard , CZECH, Joerg
IPC分类号： C07D401/12 , C07D401/14 , C07D405/14 , A61K31/4709 , A61P9/10 , A61P7/02
CPC分类号： C07D401/12 , C07D401/14 , C07D405/14
摘要： The present invention relates to compounds of the Formula (I), in which R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

7. 发明公开

EP2167487A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS 无效
标题翻译：吡咯作为P2Y12拮抗剂
公开(公告)号：EP2167487A1
公开(公告)日：2010-03-31
申请号：EP08759015.4
申请日：2008-06-04
申请人： Sanofi-Aventis
发明人： KLINGLER, Otmar , CZECH, Joerg , CZECHTIZKY, Werngard , WEISS, Tilo , JUST, Melitta
IPC分类号： C07D401/06 , C07D403/06 , C07D403/14 , C07D405/14
CPC分类号： C07D401/06 , C07D403/06 , C07D403/14 , C07D405/14
摘要： The present invention relates to compounds of the formula (I), in which R1; R2; R3; R4; R5; R6; R7; R8; R9; R10; R11; R12; R13; A; B, D and E have the meanings indicated indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

8. 发明公开

EP1648486A2 USE OF A PAK INHIBITOR FOR THE TREATMENT OF A JOINT DISEASE 审中-公开
标题翻译： PAK抑制剂FOR关节疾病治疗中的用途
公开(公告)号：EP1648486A2
公开(公告)日：2006-04-26
申请号：EP04763242.7
申请日：2004-07-15
申请人： Sanofi-Aventis Deutschland GmbH
发明人： BARRADEAU, Sebastian , BARTNIK, Eckart , CZECH, Joerg , KLATT, Andreas, R. , LEBERER, Ekkehard , LEEUW, Thomas
IPC分类号： A61K38/00 , G01N33/68 , A61P19/02
CPC分类号： A61K38/08 , A61K38/45 , C07K16/40 , G01N2333/9121
摘要： The invention refers to the use of a p21 -activated kinase (PAK) inhibitor for the treatment of a joint disease such as osteoarthritis or rheumatoid arthritis or for the treatment of a joint pain and the use of PAK as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.

9. 发明授权

EP2054412B1 IMINO-IMIDAZO-PYRIDINDERIVATE MIT ANTITHROMBOTISCHER AKTIVITÄT 有权
标题翻译：具有抗血栓形成活性亚氨基咪唑并 - 吡啶衍生物
公开(公告)号：EP2054412B1
公开(公告)日：2009-12-02
申请号：EP07765222.0
申请日：2007-07-18
申请人： Sanofi-Aventis
发明人： HEINELT, Uwe , HOFMEISTER, Armin , CZECH, Joerg
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： The invention relates to compounds of the formula (I) having antithrombotic activity which, in particular, inhibit the protease-activated receptor 1 (PAR1), processes for their preparation and the use thereof as medicament.

10. 发明公开

EP2054412A2 IMINO-IMIDAZO-PYRIDINDERIVATE MIT ANTITHROMBOTISCHER AKTIVITÄT 有权
标题翻译： IMINO-IMIDAZO-PYRIDINDERIVATE MIT抗血栓扩张剂AKTIVITÄT
公开(公告)号：EP2054412A2
公开(公告)日：2009-05-06
申请号：EP07765222.0
申请日：2007-07-18
申请人： Sanofi-Aventis
发明人： HEINELT, Uwe , HOFMEISTER, Armin , CZECH, Joerg
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： The invention relates to compounds of the formula (I) having antithrombotic activity which, in particular, inhibit the protease-activated receptor 1 (PAR1), processes for their preparation and the use thereof as medicament.
摘要翻译：本发明涉及具有抗血栓形成活性的式（I）化合物，其特别是抑制蛋白酶活化的受体1（PAR1），其制备方法及其作为药物的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式